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The trinuclear platinum cluster [Pt3(μ-PBu
t
2)3(CO)3]CF3SO3 (I) was designed featuring the presence of a nearly
equilateral platinum triangle bridged by three di-tert-butylphosphide ligands; in addition, each platinum center
bears a terminal carbonyl ligand. This triplatinum cluster was initially developed in view of applications in the
ﬁeld of cluster-containing innovative materials. Yet, due to the large success of platinum complexes in cancer
treatment, we also decided to explore its cytotoxic and anticancer properties. Accordingly, the solubility proﬁle
of this compound in several solvents was preliminarily investigated, revealing a conspicuous solubility in
DMSO and DMSO/buffer mixtures; this makes the biological testing of I amenable. UV–Vis measurements
showed that the triplatinum cluster is stable for several hours under a variety of conditions, within aqueous en-
vironments. No measurable reactivity was observed for I toward two typical model proteins, i.e. lysozyme and
cytochrome c. On the contrary, a signiﬁcant reactivity was evidenced when reacting Iwith small sulfur-contain-
ing ligands. In particular, a pronounced reactivity with reduced glutathione and cysteine emerged from ESI-MS
experiments, proving complete formation of I-GSH and I-Cys derivatives,with the loss of a single carbonyl ligand.
Starting from these encouraging results, the cytotoxic potential of Iwas assayed in vitro against a panel of repre-
sentative cancer cell lines, and potent cytotoxic propertieswere disclosed. Of particular interest is theﬁnding that
the triplatinum species manifests potent antiproliferative properties toward Triple Negative Breast Cancer Cells,
often refractory tomost anticancer drugs. Owing to the reported encouraging results, amore extensive biological
and pharmacological evaluation of this Pt cluster is now warranted to better elucidate its mode of action.
Crown Copyright © 2016 Published by Elsevier Inc. All rights reserved.
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1. Introduction
Molecular platinumclusters have been intensely investigated during
the last three decades for their attractive and peculiar chemical and
electronic properties [1–4]. A variety of Pt clusters were thus prepared
and characterised mostly containing a number of Pt atoms ranging
from 3 to 50 [5–8]. In spite of these intense research activities and of ex-
tensive literature reports, we realised that this kind of compoundswere
poorly considered for their biological actions. This situation probably
arises from the fact that Pt clusters are usually insoluble in aqueous en-
vironments and thus scarcely amenable for biomedical applications. In
addition, their main application has been, traditionally, as models of
heterogeneous platinum catalysts [9–11].
Yet, as platinumdrugs play a key role in the current chemotherapeu-
tic treatments of several cancers and as thousands of Pt analogues have
been prepared and tested so far for this purpose, wewanted to ascertain
whether selected Pt clustersmight be of interest as prospective antican-
cer agents. The triplatinum cluster [Pt3(μ-PBu
t
2)3(CO)3]CF3SO3, (I), pre-
pared and characterised a fewyears ago in our laboratory [12], appeared
to be a good candidate for this kind of investigations. Its crystal structure
had been solved earlier, and amodel of the cation is shown in Fig. 1. This
complex consists of three equidistant platinum centers connected
through bridging P donors belonging to three di-tert-butylphosphide li-
gands; in turn, each platinum center bears a carbonyl ligand.
This monocationic triplatinum cluster was ﬁrst developed in view of
its use as a building block for the synthesis of cluster-containingmolec-
ular assemblies [13]. However, as it alsomanifests an appreciable stabil-
ity in solution and sufﬁcient solubility even in aqueous environments,
we wondered whether it might be suitable for biomedical applications.
These arguments led us to study in more detail the solution behav-
iour of I and to characterise its reactivity toward a few standard biomol-
ecules. Afterward, the antiproliferative and pro-apoptotic properties of I
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were measured in vitro against a small panel of cancer cell lines with
rather encouraging results.
2. Materials and methods
2.1. Spectrophotometric experiments
UV–vis absorption spectra were recorded on a Varian Cary 50 UV–
Vis spectrophotometer (Varian, Palo Alto, CA, USA) in the range of
200–700 nm. Stock solution of I (3 × 10−3M)was prepared by dissolv-
ing the complex under investigation in DMSO.
For stability studies in solution, UV–Vis measurements were per-
formed by diluting the compound's stock solutions to 3 × 10−4 M in
DMSO. Spectra were collected during 24 and 72 h at room temperature,
operating in 10 min intervals during the ﬁrst hour and in 1 h intervals
afterward.
2.2. GSH and Cys interaction studies – electrospray ionization mass
spectrometry
The stock solution of Iwas prepared in DMSO at 1 mM and stored at
−20 °C until usage. DMSO stock solutions (10 mM) of GSH and Cys
were prepared. 100 μL of these solutions were added, separately, to
10 μL of the stock solution of I in order to obtain a 10:1 ratio. The mix-
tures were diluted with DMSO at a ﬁnal concentration of 10−4 M of I.
Samples were incubated at 37 °C for 24.
Electrospray ionization mass spectra of the mixtures were recorded
from samples generated through 20-fold dilution with H2O/CH3CN 1:1
in an LTQ-Orbitrap high-resolution mass spectrometer (Thermo, San
Jose, CA, USA), equipped with a conventional ESI source (direct intro-
duction,ﬂow rate 5 μL/min). The following standardizedworking condi-
tions were applied: spray voltage 3.1 kV, tube lens voltage 230 V,
capillary voltage 45 V, and capillary temperature 220 °C. Sheath and
auxiliary gases were set at 17 au and 1 au, respectively. Data was ac-
quiredwith a nominal resolution of 100,000 (atm/z 400), usingXcalibur
2.0 software (Thermo).
2.3. Biological experiments
2.3.1. Cell cultures
MDAMB231, MCF7 cell lines were cultured in DMEM (Euroclone;
Milan, Italy) with 10% Fetal Bovine Serum (FBS) (Euroclone Deﬁned;
Euroclone; Milan, Italy). HCT-116, FLG 29.1, L929 and HL60 were cul-
tured in RPMI 1640 (Euroclone; Milan, Italy) with 10% Fetal Bovine
Serum (FBS) (Euroclone Deﬁned; Euroclone; Milan, Italy). HCT116
cells were kindly provided by Dr. R. Falcioni (Regina Elena Cancer Insti-
tute, Roma). We cultured the cell lines at 37 °C under a humidiﬁed at-
mosphere in 5% CO2 in air.
2.3.2. Pharmacology experiments
Cells were seeded in a 96-well ﬂat-bottomed plate (Corning-Costar,
Corning, NY, USA) at a cell density of 1 × 104 cells per well in either
RPMI or DMEM complete medium. The compound I was used, after
solubilisation in water without DMSO, in range of concentration of 0–
200 nM. After 24 h and 48 h, viable cells (determined by Trypan blue ex-
clusion) were counted in triplicate using a haemocytometer. Each ex-
perimental point represents the mean of a single experiment carried
out in triplicate.
2.3.3. Trypan blue assay
Cells viability was assessed by the Trypan blue exclusion assay. In
brief, 10 μL of 0.4% trypan blue solution was added to 10 μL cell suspen-
sions in culture medium. The suspension was gently mixed and trans-
ferred to a haemocytometer. Viable and dead cells were identiﬁed and
counted under a light microscope. Blue cells failing to exclude the
dyes were considered nonviable, and transparent cells were considered
viable. The percentage of viable cells was calculated on the basis of the
total number of cells (viable plus nonviable).
The IC50 value (i.e., the dose that caused apoptosis of 50% of cells)
was calculated by ﬁtting the data points (after 24 h and 48 h of incuba-
tion) with a sigmoidal curve using Calcusyn software (Biosoft, Cam-
bridge, UK).
3. Results and discussion
3.1. Chemistry: solution behaviour and reactivity
The solubility proﬁle of complex I was investigated in a variety of
solvents. Beyond being soluble in some organic solvents like DCM and
acetone, this compound also manifested an appreciable solubility in
DMSO and, also, in DMSO/aqueous buffer mixtures.
The stability behaviour of the triplatinum cluster in these latter sol-
vents wasmonitored over time by UV visible spectroscopy. As shown in
Fig. 2, this compound exhibits a typical absorption spectrum in the UV–
Visible, characterised by the presence of four resolved bands at 280, 310,
330 and 380 nm. The triplatinum species was found to be stable during
the ﬁrst 12 h at 25 °C.
Anyway, upon extending the stability study in DMSO up to 72 h at
25 °C, some major changes in the UV–Vis spectrum became evident
(see Fig. 2). In fact, a decrease of the bands located at 310, 330 and
380 nm is detected with a concomitant growing up of the bands at
250 and 440 nm. In addition, an isosbestic point is present, in the visible,
at 420 nm.
Fig. 1. Structure of complex I.
Fig. 2. UV–Vis absorption spectra of a 3 × 10−4 M solution of I in DMSO recorded during
72 h. The group of traces included with the red line are referred to the ﬁrst 12 h; blue
line, 24 h; green line, 48 h; pink line, 72 h.
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Afterward, we analysed the reactivity of Iwith small proteins and a
few lowmolecularweight biomolecules. ESI-MS turned out to be an op-
timal tool for this kind of investigation according to previous experience
of our laboratory [14–16]. The ESI-MS spectrum of I, in CH3CN solution,
reveals the characteristic isotopic pattern (see Fig. 3). No adduct forma-
tion was detected by ESI-MS when I was challenged against the two
model proteins cyt-c and lysozyme, even after long incubation times.
Yet,when reactedwith small sulfur-containing ligands, a clear reactivity
was highlighted. In particular, quantitative formation of stable deriva-
tives with GSH and Cys was demonstrated by the ESI-MS experiments
shown in Fig. 4.
Indeed, from inspection of the ESI-MS spectra shown in Fig. 4, the
high reactivity of I toward both sulfur-containing small molecules is un-
ambiguously documented. In fact, the peak at m/z 1383.31 (panel A)
could be assigned to the I-GSH complex, with the loss of only one CO
group. In the same manner, the peak at m/z 1197.25 (panel C) was at-
tributed to the I-Cys adduct. Even in this case the loss of one CO group
occurs that is most probably displaced by a sulfur donor. Analysis of
themeasured isotopic pattern conﬁrmed the formation of the twomen-
tioned adducts (panel B and D, respectively). In addition, either in case
of GSH or of Cys, the ESI-MS experiments did not reveal the presence
of unreacted I nor the formation of adducts of Iwithmore than onemol-
ecule of GSH or Cys.
3.2. Biological studies
Having documented such an interesting behaviour of complex I in
aqueous solution and its selectivity in biomolecular reactions, we decid-
ed to evaluate the cellular effects of complex I against a representative
panel of cancer cell lines. The cancer cell panel included the following
cell lines: MDAMB231 and MCF7 (human breast cancer), HL60 and
FLG 29.1 (human acute myeloid leukemia), and a series of cell lines
(human colorectal adenocarcinoma) showing different sensitivity to
cisplatin i.e. HCT116, HCT8 and HT29.
To determine the cytotoxic effect of the triplatinum cluster on the
above cancer lines we used the Trypan blue method as detailed in the
experimental section. Following a preliminary appreciation of its potent
antiproliferative effects, the biological activity of compound I was
assessed at seven different concentrations in the nanomolar range,
(i.e. 0.5 nM, 1 nM, 5 nM, 10 nM, 20 nM, 50 nM, 100 nM) after 24 and
48 h incubation. Analysis of the corresponding growth curves according
to Chou Talalay algorithm allows determination of the respective IC50
values, that are reported in Table 1. The extremely high antiproliferative
potential of this compound is thus demonstrated. The IC50 values are
higher after 48 h of treatment, suggesting that the tested cancer cells
are able to reverse, i.e. repair, at least partially, the insult. As this behav-
iour differs from cisplatin for which IC50 values at 48 h are generally
smaller than those recorded at 24 h, these results offer some initial evi-
dence that themodeof action of the triplatinumclustermarkedly differs
from cisplatin.
Fig. 3. ESI-MS spectrum of I; panel A –measured, panel B – theoretical.
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Moreover, the cytotoxic activity against non-cancerous cell line L929
(mouse ﬁbroblast), was also assessed in the same conditions. Normal
cells turned out to be less sensitive to compound I than cancer cells
(IC50 167.3 ± 8.67 nM). Tumour selectivity values, calculated as the
IC50 values for primary cultures divided by the IC50 values for the cancer
cells, are in the range between 19.25 (MCF7) and 3.68 (HCT116). These
data clearly indicate that the experimental compound I possesses a
moderate to pronounced selectivity for tumour cells. In the same exper-
imental conditions three cancer cell lines, HCT116, HT29 andHCT8were
also tested that possess variable sensitivity to cisplatin, respectively (see
Table 1). The obtained data clearly showed that cell line less sensitive to
cisplatin has the lower IC50 for compound I.
The cell lines were exposed to increasing concentrations of com-
pound I in the range 0–200 nM. After 24 and 48 h, viable cells (deter-
mined by Trypan blue exclusion) were counted in triplicate using a
haemocytometer. Each experimental point represents the mean of
four samples carried out in three separate experiments.
We next evaluated the effect of compound I in the induction of apo-
ptosis in HCT116 cells by the Annexin/PI test. The treatment with com-
pound I for 48 h caused an evident induction of apoptosis as shown in
Fig. 5.
4. Conclusions
From these initial studies it can be stated that the investigated
triplatinum cluster manifests an appreciable stability within various
physiologicalmedia and exhibits, at the same time, very potent antipro-
liferative effects in a panel of representative tumour cell lines. It is re-
markable that a very potent cytotoxic action is detected also toward
the triple negative MDAMB231 cells, a kind of cancer cell line often re-
fractory to several medical treatments. It will be of interest in the next
future to perform further studies to better understand the mode of ac-
tion of this novel and peculiar Pt complex. It is particularly relevant to
determine whether the cluster acts in its intact form, i.e. as a trimetallic
Fig. 4. ESI-MS spectra of I in DMSO incubated with GSH (A) and Cys (B) with their characteristic isotopic patterns (B and D, respectively).
Table 1
IC50 values for compound I in a panel of leukemia cell lines and solid tumour cell lines.
Cell line Type
IC50
(nM) 24 h
IC50
(nM) 48 h
IC50
Cisplatin (μM)
MDAMB231 Breast cancer 16.3 ± 0.8 19.6 ± 1.1 82.5 + 3.2
MCF7 Breast cancer 8.7 ± 1.1 32.1 ± 1.2 −
HL60 Acute leukemia 22.5 ± 0.8 37.8 ± 1.4 −
FLG 29.1 Acute leukemia 31.6 ± 0.9 69.5 ± 2.4 24.4 ± 0.8
HCT116 Colorectal adenocarcinoma 45.4 ± 6.5 61.2 ± 3.7 25.5 ± 2.1
HT-29 Colorectal adenocarcinoma 130.0 ± 14.5 − 16.6 ± 0.9
HCT-8 Colorectal adenocarcinoma 92.0 ± 7.1 − 8.7 ± 1.4
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species, or undergoes degradation in the cellular environment releasing
monometallic Pt species.
Abbreviations
Cys cysteine
DCM dichloromethane
DMEM Dulbecco's Modiﬁed Eagle Medium
DMSO dimethyl sulfoxide
ESI-MS electrospray ionization mass spectrometry
GSH reduced glutathione
HER2 human epidermal growth factor receptor 2
MCF 7 Michigan Cancer Foundation-7
PI propidium iodide
RPMI Roswell Park Memorial Institute medium
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panel = control (early apoptotic cells, Annexin+/PI−: 0%; late apoptotic cells, Annexin+/PI+: 0%); right panel = treated with compound I (early apoptotic cells, Annexin+/PI−: 12%;
late apoptotic cells, Annexin+/PI+: 39%).
5C. Gabbiani et al. / Journal of Inorganic Biochemistry xxx (2016) xxx–xxx
Please cite this article as: C. Gabbiani, et al., Potent in vitro antiproliferative properties for a triplatinum cluster toward triple negative breast
cancer cells, J. Inorg. Biochem. (2016), http://dx.doi.org/10.1016/j.jinorgbio.2016.06.024
